Prevalence of the epidermal growth factor receptor mutations in lung adenocarcinoma patients from the Middle East region

Arafat Hussein Tfayli, Ghina Bassam Fakhri, Majd Sassine Al AssaadAnnals of Thoracic Medicine 2019 14(3):173-178 Lung cancer remains a major cause of cancer mortality with a 5-year survival in advanced stages around 4%. Platinum-based chemotherapy was routinely used as the standard of care in patients with advanced nonsmall cell lung cancer, but it is being progressively replaced by targeted molecular therapy. One of the molecular aberrations harbored by lung adenocarcinoma is the epidermal growth factor receptor (EGFR). A large ethnic variation has been reported in the prevalence of EGFR mutations in patients with lung adenocarcinoma. Data regarding its prevalence from the Middle East area remains limited. This paper aims at reviewing the data available for the prevalence of this mutation in the Middle Eastern patient population and comparing it with other reported series.
Source: Annals of Thoracic Medicine - Category: Respiratory Medicine Authors: Source Type: research